Josh Mailman Joins NETRF Board of Directors

The NETRF Board of Directors is pleased to announce that Josh Mailman has joined the Board. Josh is an internationally-recognized advocate for Neuroendocrine tumor patients as well as an advocate for integrative oncology and nuclear medicine and molecular imaging.

He is the inaugural chairman of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Patient Advocacy Advisory Board, a member of The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) Board and president of NorCal CarciNET Community, one of the largest NET patient groups in the United States. In addition he has been a member of the National Cancer Institute’s Task Force on Neuroendocrine Tumors for over 3 years.

Josh is one of the most committed, effective, and respected leaders in the NET community, said Ron Hollander, NETRF Executive Director. “We are looking forward to having his perspective and his passion on our Board to help us accelerate our research for better treatments and cures for neuroendocrine cancers.”

In 2015, Josh was honored with the WARNER ADVOCACY AWARD, given annually by Novartis Oncology Patient Advocacy and The NET Alliance. The award recognizes an individual for leadership and advocacy for neuroendocrine patients. In the same year Josh was given the SNMMI’s President’s Award for his work on behalf of patients in the Nuclear medicine field. Josh is a former executive board member of the Society for Integrative Oncology (SIO) and was named SIO Patient Advocate of Year in 2010.
Josh has an MBA from the Anderson School of Management at UCLA and has been a technology entrepreneur for more than 20 years. Josh lives in Oakland, California with his wife Juliette and their ten year-old son.

I am honored to join the NETRF board”, said Josh “Over the past several years NETRF has laid the foundations for researchers and institutions to cooperate around the world. With the recent contributions by major donors NETRF will be able to leverage this infrastructure to support research that will lead towards new treatments that will extend and improve our lives.